News & Announcements

Weil Serves as Antitrust Counsel to Allergan in the $40.5 Billion Sale of its Global Generic Pharmaceuticals Business

Weil’s Antitrust team is representing Allergan plc, a leading global pharmaceutical company, in the recently announced sale of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd., a transaction valued at approximately $40.5 billion. “This transaction will accelerate Allergan's evolution into a branded Growth Pharma leader,” said Brent Saunders, CEO and President of Allergan, in a press release.

Weil previously served as antitrust counsel to Allergan in its approximately $2.1 billion acquisition of KYTHERA Biopharmaceuticals Inc. In addition, Weil served as antitrust counsel to Actavis plc in its approximately $70.5 billion acquisition of Allergan, the combined company assumed the Allergan name.

Weil’s Antitrust team includes partners Steven Newborn, Ann Malester and Jeff White and associates Brianne Kucerik, Daniel Antalics and Benjamin Bauer.

For more information on the transaction, view Allergan’s press release.